MedTrace Logo

Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras

NCT04771013 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2022-02-04

Study results available
· View outcomes & findings →

Summary

This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.

Conditions

Interventions

BIOLOGICAL

Thymic peptides

250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.

Sponsors & Collaborators

  • Pontificia Universidad Catolica de Chile

    collaborator OTHER

  • Universidad Católica de Honduras

    lead OTHER

Principal Investigators

  • Héctor M Ramos, MD · Universidad Católica de Honduras; Pontificia Universidad Católica de Chile

  • Karla G Reyes, MD · Universidad Católica de Honduras; Universidad Mayor

  • Nelson A Espinoza, MD · Universidad Católica de Honduras

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-10
Primary Completion
2021-05-14
Completion
2021-05-14

Countries

  • Honduras

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04771013 on ClinicalTrials.gov